Definium Therapeutics (DFTX) announced the appointment of Roger Adsett to its Board of Directors. Adsett currently serves as COO of Insmed (INSM). The appointment increases the board from six to seven directors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DFTX:
- Definium Therapeutics Expands Board, Appoints New Director
- Definium Therapeutics price target raised to $37 from $16 at Baird
- Definium Therapeutics price target raised to $36 from $20 at RBC Capital
- Psychedelic: Analyst initiates Atai Beckley with Buy rating
- Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry